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First- and second-generation immunometric PTH assays during
treatment of hyperparathyroidism with cinacalcet HCl.
Background. First-generation immunometric assays for
“intact” parathyroid hormone (iPTH) also measure large
N-terminally truncated PTH fragments, whereas second-
generation assays, such as the “bio-intact” PTH (biPTH) assay,
measure only full-length biologically active PTH(1–84). This
study compared iPTH and biPTH assays during cinacalcet treat-
ment in subjects with secondary HPT receiving dialysis.
Methods. Four hundred and ten subjects were enrolled in a
26-week randomized, double-blind, placebo-controlled trial of
oral cinacalcet (or placebo), 30 to 180 mg once daily, and efficacy
was assessed using biPTH and iPTH assays.
Results. Compared with control treatment, cinacalcet im-
proved the management of secondary HPT. Both biPTH and
iPTH decreased by 38% ± 3% during weeks 13 to 26 in the
cinacalcet group; biPTH increased by 23% ± 4% and iPTH in-
creased by 9.5% ± 3% in the control group (P < 0.001). Fifty-
six percent of cinacalcet subjects and 10% of control subjects
had a ≥30% reduction in biPTH, and 61% and 11%, respec-
tively, had a ≥30% reduction in iPTH. Significant correlations
between biPTH and iPTH levels were observed throughout the
study. Both assays correlated similarly with bone-specific alka-
line phosphatase levels. The ratio of biPTH to iPTH was main-
tained at 56% ± 1% after treatment in both treatment groups.
Increasing serum calcium levels were associated with a decreas-
ing ratio of biPTH to (iPTH–biPTH).
Conclusion. These data show that PTH can be monitored
with either iPTH or biPTH assays during therapy with cinacal-
cet, and that cinacalcet therapy does not exert a major influence
on the ratio between PTH(1–84) and large, N-terminally trun-
cated PTH fragments.
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Measurements of parathyroid hormone (PTH) are
essential for the diagnosis of secondary hyperparathy-
roidism (HPT) and for monitoring the patient’s response
to therapy. In addition, measurement of PTH helps avoid
oversuppression of PTH secretion that contributes to
adynamic bone disease [1–5], an increased risk of frac-
tures in adults, and further impairment of longitudinal
growth in children [6–8]. Measurement of PTH using the
first-generation immunometric assay has been the most
commonly used method over the past decade to diagnose
and treat secondary HPT.
First-generation immunometric assays for PTH em-
ploy 2 antibodies; the detection antibody is directed to-
ward an epitope within the N-terminal region of PTH,
while the capture antibody is directed toward an epitope
within the C-terminal region of PTH [1, 9]. Initially, first-
generation immunometric assays were thought to detect
exclusively full-length PTH(1–84), thus, the term “in-
tact” PTH (iPTH) assay. Subsequently, it was found that
such assays also detect large N-terminally truncated frag-
ments, which behave on high-performance liquid chro-
matography (HPLC) similarly to PTH(7–84) [10, 11].
These large PTH fragments have not yet been defined
chemically, but in patients with renal failure, they appear
to be present in higher concentrations than in normal sub-
jects [10–12]. Animal studies suggest this may be because
of a somewhat reduced clearance of PTH fragments by
the kidney and/or increased secretion of fragments from
the parathyroid gland [13, 14].
Second-generation immunometric PTH assays were
developed by different laboratories using detection an-
tibodies that specifically recognize the first 1 or 2 N-
terminal amino acids of PTH, and capture antibodies that
recognize an epitope within the C-terminal region. The
resulting sandwich assays are thus likely to exclusively de-
tect the full-length, biologically active PTH molecule [i.e.,
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PTH(1–84)] [15–17], unless PTH fragments truncated at
the C-terminus are also present. Although theoretically,
such second-generation PTH immunometric assays [e.g.,
Bio-Intact PTH Assay (Nichols Institute, San Clemente,
CA, USA) (biPTH) [9], Whole PTH Assay (Scantibod-
ies, San Clemente, CA, USA) [16], and Bioactive Intact
PTH Assay (Immutopics, San Clemente, CA, USA)] [17],
should be superior to the first-generation “intact” PTH
assay, most current data suggest that PTH levels mea-
sured with either assay system provide a similar predic-
tion of bone turnover in patients with end-stage renal
disease (ESRD) [17].
Oral calcimimetic agents are small molecules that di-
rectly and rapidly lower PTH secretion by binding di-
rectly to the calcium-sensing receptor on chief cells in the
parathyroid gland and increasing its sensitivity to extra-
cellular ionized calcium [18]. Cinacalcet HCl (Sensipar,
Mimpara, hereafter cinacalcet; Amgen, Inc., Thousand
Oaks, CA, USA), the first calcimimetic agent to be eval-
uated in clinical trials for the management of secondary
HPT [19–21], has recently been approved in the United
States, Canada, and Europe for the treatment of sec-
ondary HPT in dialysis patients. The PTH values used
in those studies to manage dose adjustments in cinacal-
cet therapy and to evaluate the efficacy of cinacalcet were
measured using a first-generation PTH immunometric as-
say (iPTH Assay; Nichols Institute). The present analysis
was conducted to determine whether second-generation
PTH assays can be used to evaluate response to cinacal-
cet therapy with similar accuracy as first-generation as-
says, and to estimate the conversion factor from iPTH to
biPTH levels during cinacalcet therapy. In addition, we
sought to determine if demographic and laboratory pa-
rameters influence the ratio of biPTH to (iPTH–biPTH).
METHODS
Subjects
This prospective, multicenter, randomized, placebo-
controlled trial was conducted at 65 centers in the United
States and Canada. The primary inclusion criteria were
age ≥18 years, thrice-weekly hemodialysis for at least 3
months, mean plasma iPTH level ≥300 pg/mL despite
ongoing treatment with diet, vitamin D therapy, and/or
phosphate-binding therapy, and mean serum calcium
level ≥8.4 mg/dL. Enrollment of subjects with plasma
iPTH >800 pg/mL at baseline was limited to 20% of the
population. All subjects provided informed written con-
sent to participate, and institutional review boards ap-
proved the study design.
Study design
Eligible subjects were randomly (computer-generated
randomization) assigned in a 1:1 ratio to double-blind
treatment with cinacalcet or matching placebo taken
orally once daily; randomization was stratified by base-
line iPTH and Ca × P level. Blood for biochemical mea-
surements was drawn weekly from weeks 1 to 12 and
then biweekly from weeks 13 to 26. Plasma PTH concen-
trations were measured by a first-generation assay, the
Intact PTH Assay (iPTH) (Nichols Institute), which de-
tects PTH(1–84) as well as PTH(7–84) [9, 15–17], and
by a second-generation Bio-Intact PTH (biPTH) Assay
(Nichols Institute), which detects PTH(1–84) [9]. The
biPTH to iPTH ratio was determined by dividing
the value obtained from the Bio-Intact PTH Assay by the
value obtained from the Intact PTH Assay. The biPTH
to (iPTH–biPTH) ratio was determined by dividing the
value obtained from the Bio-Intact PTH Assay by
the value obtained from the Intact PTH Assay minus the
value obtained from the Bio-Intact PTH Assay. Serum
bone-specific alkaline phosphatase (BALP) levels were
determined before treatment and at weeks 12 and 26.
During the first 12 weeks, cinacalcet (or placebo) doses
were titrated sequentially every 3 weeks from a starting
dose of 30 mg to doses of 60, 90, 120, and 180 mg if plasma
iPTH was >200 pg/mL and serum calcium was ≥7.8
mg/dL. The dose could be modified further as needed ev-
ery 4 weeks during weeks 13 to 26. Dose reductions were
permitted for symptomatic hypocalcemia, serum calcium
<7.5 mg/dL, plasma iPTH <100 pg/mL on 3 consecutive
study visits, or a dose-related adverse event.
Statistical analysis
Baseline values were obtained during the screening pe-
riod. Mean values for iPTH and biPTH, calcium, phos-
phorus, and Ca × P were determined from all available
results from weeks 13 to 26 (up to 7 values per subject).
Evaluations included the proportion of subjects with an
average iPTH ≤250 pg/mL and biPTH ≤140 pg/mL from
weeks 13 to 26, and the proportion of subjects with an
average iPTH and biPTH level from weeks 13 to 26 that
was reduced by ≥30% from baseline. Subjects who with-
drew before week 13 were included in the analysis and
considered not to have met the study end points. The pro-
portions of subjects who met the therapeutic end points
were compared between groups by a Cochran-Mantel-
Haenszel test, stratified by iPTH and Ca × P level at
baseline.
Mean percentage changes in biPTH and iPTH from
baseline were determined at each visit. The mean per-
centage changes from baseline during weeks 13 to 26 were
compared between groups by a generalized Cochran-
Mantel-Haenszel test using rank, stratified by iPTH and
Ca × P values at baseline. The mean of the last 2 on-study
values was carried forward for subjects who withdrew be-
fore week 13.
Correlation and linear regression analyses of plasma
biPTH and iPTH values were performed for randomized
subjects in each treatment group at baseline, as well as for
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mean biPTH and iPTH values provided during weeks 13
to 26 to estimate the relationship between biPTH and
iPTH values. Regression lines were fitted through the
intercept of biPTH and iPTH. Subjects who withdrew
from the study before week 13 were excluded from this
analysis.
The linear regression analyses of biPTH to (iPTH–
biPTH) were performed using mean values during weeks
13 to 26 or values at week 26, if appropriate. Data lines
associated with negative (iPTH–biPTH) values (1.9% of
the values) were removed before calculating means. Re-
gression lines were fitted through the intercept of biPTH
and (iPTH–biPTH) with treatment group and several de-
mographic and laboratory variables as covariates. The
difference in ratio of biPTH to (iPTH–biPTH) [i.e., co-
efficients of (iPTH-biPTH) in linear regression] between
covariate subgroups and between treatment groups was
tested for statistical significance using the contrast option
within SAS procedure PROC GLM. The factors investi-
gated were age, sex, race, coexistent diabetes, duration of
dialysis, serum concentrations of calcium and phospho-
rus, BALP level, vitamin D use, and phosphate binder
type used. All analyses were performed using SAS ver-
sion 8.2 (Cary, NC).
RESULTS
Study participants
Baseline demographics and clinical characteristics of
the study participants were not significantly different be-
tween treatment groups at baseline (Table 1). Mean ± SD
age was 53.8 ± 14.4 years, 60% of subjects were male, 58%
were black, 32% were white, and 10% were of other races.
Participants had received dialysis treatment for an aver-
age of 64 months (range 0.5–290 months) before study
entry. The mean ± SD plasma biPTH value at baseline
was 332 ± 214 pg/mL (range 103–1712 pg/mL) and iPTH
was 643 ± 370 pg/mL (range 299–2644 pg/mL). Mean
± SD serum calcium, phosphorus, and Ca × P values at
baseline were 9.9 ± 0.78 mg/dL, 6.3 ± 1.7 mg/dL, and 61.6
± 16.1 mg2/dL2, respectively.
At baseline, 69% of subjects were receiving vitamin
D sterols. During the 6-month treatment period, 83%
of subjects received at least 1 dose of vitamin D sterols
and 98% received at least 1 dose of phosphate binders.
Seventy-one percent of cinacalcet-treated subjects and
77% of control group subjects completed 26 weeks of
treatment.
Response to treatment
Response to cinacalcet therapy was similar whether as-
sessed using the biPTH or iPTH assay (Table 2). Mean
concentrations of biPTH and iPTH during weeks 13 to 26
each decreased 38% ± 3% from baseline in cinacalcet-
treated subjects (P < 0.001 vs. baseline). Control treat-
ment during this same period was associated with mean
Table 1. Baseline demographics and clinical characteristics
Cinacalcet Control
(N = 205) (N = 205) P valuea
Age years ± SD 53 ± 14 54 ± 15 0.504
Gender%
Male/female 60/40 60/40 > 0.999
Race%
White/black/other 30/59/11 34/58/8 0.666
Time on dialysis months ± SD 67 ± 56 62 ± 55 0.374
Vitamin D sterol use% 70 68 0.593
Calcitriol 8 9
Paricalcitol 44 45
Oral calcitriol 6 5
Combined vitamin D therapy <1 0
Other 11 9
Phosphate binder use% 94 95 0.661
Calcium-containing only 37 41
Sevelamer only 38 36
Calcium-containing/ 15 13
sevelamer combination
Other binders 4 5
aP value determined using Student t tests for continuous variables or
chi-squared tests for categorical variables.
increases in biPTH and iPTH of 23% ± 4% and 10% ±
3%, respectively (P < 0.001 vs. cinacalcet). Reductions
in biPTH paralleled reductions in iPTH in the cinacal-
cet group throughout the study, with mean biPTH reduc-
tions ranging from 34% to 46% and mean iPTH reduc-
tions ranging from 37% to 46% at each visit from weeks
13 to 26 (Fig. 1). In the control group, mean biPTH in-
creased by 19% to 24% from baseline during weeks 13 to
26 and mean iPTH increased by 6% to 13%. Cinacal-
cet therapy significantly reduced mean concentrations
of serum calcium and phosphorus during weeks 13 to
26, compared with control (P < 0.001 and P < 0.013;
Table 2). As would be expected, cinacalcet resulted in a
significant (P < 0.001) reduction in Ca × P as well.
Cinacalcet reduced mean biPTH to ≤140 pg/mL in
45% of subjects, whereas only 8% of subjects in the con-
trol group (P < 0.001) achieved this reduction. More-
over, 39% of subjects in the cinacalcet group compared
with only 3% of those in the control group experienced
both a reduction in biPTH to ≤140 pg/mL and a reduc-
tion from baseline in Ca × P (P < 0.001). In addition,
56% of subjects in the cinacalcet group achieved a ≥30%
reduction in biPTH from baseline, compared with 10%
of subjects in the control group (P < 0.001). Similar re-
sults were observed when the iPTH assay was used to
monitor response to therapy in the cinacalcet and con-
trol subjects [≤250 pg/mL (41% vs. 4%, P < 0.001), ≤250
pg/mL with Ca × P reduced (37% vs. 1%, P < 0.001),
and ≥30% iPTH reduction (61% vs. 11%, P < 0.001)],
respectively.
Correlation between PTH assays and correlation with
BALP
Regression analyses of plasma biPTH and iPTH val-
ues within each group resulted in highly significant
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Table 2. Key efficacy results for intact parathyroid hormone (iPTH), bio-intact PTH (biPTH), calcium and phosphorus
Cinacalcet (N = 205) Control (N = 205)
Mean ± SD Median (IQR)a Mean ± SD Median (IQR)a P valueb
Plasma iPTH
Baselinec 636 ± 24 537 (399; 720) 646 ± 28 535 (393; 740) 0.711
Weeks 13-26d 385 ± 25e 275 (173; 448)e 698 ± 33 563 (378; 839) <0.001
Percent change −38.4 ± 2.9 −48 (−67; −19) 9.5 ± 2.8 4 (−15; 30)
Plasma biPTH
Baselinec 328 ± 14 266 (206; 363) 335 ± 16 276 (201; 366) 0.784
Weeks 13-26d 200 ± 15e 134 (78; 239)e 396 ± 18e 326 (207; 503)e <0.001
Percent change −38 ± 3 −49 (−70; −18) 23 ± 4 16 (−10; 46)
Serum calcium
Baselinec 9.8 ± 0.1 9.8 (9.3; 10.4) 9.9 ± 0.1 9.8 (9.4; 10.4) 0.888
Weeks 13-26d 9.2 ± 0.1e 9.1 (8.6; 9.6)e 9.9 ± 0.1 9.9 (9.4; 10.6) < 0.001
Percent change −6.3 ± 0.6 −5.5 (−13; −1) 0.5 ± 0.3 0.5 (−2; 4)
Serum phosphorus
Baselinec 6.3 ± 0.1 6.1 (5.3; 7.2) 6.2 ± 0.1 6.3 (5.1; 7.1) 0.331
Weeks 13-26d 5.7 ± 0.1e 5.6 (4.7; 6.5)e 6 ± 0.1 6.0 (5.2; 6.9) 0.013
Percent change − 7.1 ± 1.7 −9 (−23; 5.9) 1.1 ± 1.8 −1 (−16; 12)
aInterquartile range, reported as (25th, 75th) percentile of measured values.
bBetween-group comparisons were performed using a generalized Cochran-Mantel-Haenszel test, stratified by baseline parathyroid hormone and dialysis modality.
cBased on 3 measurements during the screening period.
dThe last 2 on-study values were carried forward for patients who withdrew during the titration phase.
eP < 0.001 vs. baseline, using a one-sample t test.
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Fig. 1. Parathyroid hormone control by
study treatment and study visit. Mean per-
cent change from baseline in plasma in-
tact parathyroid hormone (iPTH, closed sym-
bols) and plasma bio-intact parathyroid hor-
mone (biPTH, open symbols) during cinacal-
cet treatment (circles) and control treatment
(triangles). B, baseline.
(P < 0.001) correlations at baseline (cinacalcet r = 0.877,
P < 0.001; control r = 0.950, P < 0.001). Similarly sig-
nificant correlations (P < 0.001) were observed between
mean plasma biPTH and iPTH values during weeks 13 to
26 of treatment (cinacalcet r = 0.962, P < 0.001; control
r = 0.949, P < 0.001). The ratio of biPTH to iPTH was
52% ± 1% at baseline. During weeks 13 to 26, the ratio of
biPTH to iPTH was 56% ± 1% in both the cinacalcet and
control treatment groups. Both the biPTH and iPTH lev-
els were significantly (P < 0.001) correlated with BALP
levels at baseline, at the end of dose titration (week 12),
and at the end of treatment (week 26) (Table 3), with the
Pearson coefficients being higher for the cinacalcet group
than the control group at both week 12 and week 26.
Influence of demographic and disease factors on the ratio
of biPTH to (iPTH–biPTH)
The ratio of biPTH to (iPTH–biPTH) was 1.15 ± 0.04
during weeks 13 to 26 in the cinacalcet treatment group
and 1.20 ± 0.03 in the control group (P = 0.362). Table
4 summarizes the analyses of demographic and clinical
parameters that could have influenced the relationship
between biPTH and (iPTH–biPTH) in either treatment
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Table 3. Pearson correlation coefficients between bone-specific
alkaline phosphatase (BALP) and intact parathyroid hormone
(iPTH) or bio-intact parathyroid hormone (biPTH)
Cinacalcet Control
(N = 205) (N = 205)
biPTH iPTH biPTH iPTH
and BALP and BALP and BALP and BALP
Baseline 0.55a 0.54a 0.51a 0.49a
Week 12 0.69a 0.61a 0.53a 0.58a
Week 26 0.73a 0.69a 0.42a 0.43a
a P < 0.001 for the correlation of biPTH and BALP or iPTH and BALP.
Table 4. Estimated mean (SE) ratio of biPTH/(iPTH-biPTH) by
demographic and clinical characteristicsa
N Cinacalcet N Control P valueb
Race
White 52 1.09 (0.10) 57 1.11 (0.05) 0.82
Non-white 117 1.16 (0.05) 115 1.23 (0.03) 0.25
P valuec 0.52 0.05
Sex
Male 106 1.11 (0.05) 105 1.20 (0.03) 0.13
Female 63 1.22 (0.07) 67 1.18 (0.05) 0.62
P valuec 0.21 0.67
Age
<65 years 125 1.22 (0.05) 122 1.21 (0.03) 0.82
≥65 years 44 0.91 (0.09) 50 1.14 (0.06) 0.03
P valuec 0.002 0.32
Duration of dialysis
0 to ≤2 years 43 0.94 (0.09) 45 1.16 (0.06) 0.04
2 to ≤5 years 54 1.31 (0.09) 67 1.16 (0.04) 0.14
>5 years 72 1.17 (0.06) 60 1.24 (0.04) 0.35
P valuec 0.01 0.36
Diabetes
No 102 1.15 (0.05) 104 1.21 (0.03) 0.32
Yes 67 1.15 (0.08) 68 1.16 (0.05) 0.89
P valuec 0.96 0.38
aEstimates of ratios [i.e., coefficients of (iPTH-biPTH)] and statistical
tests are from linear regression models by including biPTH as outcome and
(iPTH–biPTH), treatment, 1 baseline characteristic, and their interactions as
predictors.
bAcross treatment group P value.
cWithin treatment group P value for the effect of demographic or clinical
characteristics.
group. The ratio between biPTH and (iPTH–biPTH) was
somewhat higher in non-white patients in the cinacalcet
group (1.09 vs. 1.16, for white and non-white respectively,
P = 0.52) and this difference approached significance
in the control group (1.11 vs. 1.23, P = 0.05). Men and
women had a similar ratio of biPTH to (iPTH–biPTH)
in the cinacalcet group (1.11 vs. 1.22, P = 0.21) and in
the control group (1.20 vs. 1.18, P = 0.67). Subjects who
were 65 years of age or older had a lower ratio of biPTH
to (iPTH–biPTH) compared with younger subjects in the
cinacalcet group (0.91 vs. 1.22, P = 0.002); the ratio was
not significantly different by age in the control group (1.14
vs. 1.21, P = 0.32).
No clear relationship between the ratio of biPTH to
(iPTH–biPTH) with increasing duration of dialysis at
baseline was observed. Diabetes was not associated with
Table 5. Estimated mean (SE) ratio of biPTH/(iPTH-biPTH) by
on-study biochemical characteristics or concomitant medication use
at weeks 13 to 26a
N Cinacalcet N Control P valueb
Calcium level
≤ 9.5 mg/dL 121 1.23 (0.05) 52 1.31 (0.05) 0.30
> 9.5 mg/dL 48 0.97 (0.08) 120 1.16 (0.03) 0.02
P valuec 0.004 0.01
Phosphorus level
≤ 5 mg/dL 57 1.00 (0.12) 35 1.14 (0.06) 0.29
> 5 to ≤ 6 mg/dL 51 1.02 (0.08) 54 1.16 (0.05) 0.14
> 6 mg/dL 61 1.25 (0.06) 83 1.23 (0.04) 0.74
P valuec 0.03 0.40
BALP
≤ 15 ng/mL 64 1.00 (0.13) 43 1.20 (0.09) 0.21
> 15 to ≤ 25 ng/mL 51 1.01 (0.07) 39 1.17 (0.08) 0.14
> 25 ng/mL 39 1.27 (0.06) 76 1.22 (0.03) 0.40
P valuec 0.01 0.83
Vitamin D use
at week 26d
No 50 0.97 (0.09) 56 1.23 (0.04) 0.006
Yes 98 1.25 (0.05) 103 1.16 (0.04) 0.163
P valuec 0.006 0.202
Phosphate binder
type used at week 26
Sevelamer 46 1.17 (0.07) 64 1.25 (0.04) 0.39
Calcium-based 59 1.17 (0.08) 60 1.23 (0.05) 0.53
P valuec 1 0.84
aEstimates of ratios [i.e., coefficients of (iPTH-biPTH)] and statistical
tests are from linear regression models by including biPTH as outcome, and
(iPTH–biPTH), treatment, 1 of the biochemical characteristics, and their
interactions as predictors.
bAcross treatment group P value.
cWithin treatment group P value for the effect of demographic or clinical
characteristics, or laboratory values.
dUnadjusted for serum calcium level.
a significant difference in the biPTH to (iPTH–biPTH)
ratio in either treatment group.
Influence of laboratory and concomitant therapy param-
eters on the ratio of biPTH to (iPTH–biPTH)
Table 5 summarizes the ratio of biPTH to (iPTH–
biPTH) according to either laboratory values or concomi-
tant therapy use at the same time PTH was measured
(weeks 13 to 26 of the study). Higher serum calcium levels
were associated with a lower ratio of biPTH to (iPTH–
biPTH) in both treatment groups (P = 0.004 and 0.01 in
the cinacalcet and control groups, respectively). In each
serum calcium subgroup, the ratio of biPTH to (iPTH–
biPTH) was lower in the cinacalcet group than in the
control group. Higher serum phosphorus levels were as-
sociated with higher ratios of biPTH to (iPTH–biPTH)
in the cinacalcet group (P = 0.01). A nonsignificant trend
was observed in the control group. A higher level of
BALP was associated with a higher ratio of biPTH to
(iPTH–biPTH) in the cinacalcet group at week 26 (P =
0.01), but no relationship between BALP levels and this
ratio was observed in the control group. A higher ratio
of biPTH to (iPTH–biPTH) was observed in cinacalcet
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subjects who received vitamin D sterols at week 26 (P =
0.006). When the vitamin D analyses were controlled for
calcium levels, no significant effect of vitamin D use on
the ratio was observed in the cinacalcet treatment group
(P = 0.919 and 0.207 in the cinacalcet and control groups,
respectively). Finally, no significant effect on the biPTH
to (iPTH–biPTH) ratio of phosphate binder type used
was observed.
Concomitant therapy use
There were no significant differences between treat-
ment groups in the number of subjects who received vi-
tamin D or phosphate binders at baseline and week 26.
Vitamin D sterols were administered to 66% (136/205)
and 65% (134/205) of subjects in the cinacalcet and con-
trol groups, respectively, at baseline. At week 26, vita-
min D sterols were administered to 66% (98/148) of
cinacalcet subjects and 65% (104/161) of control sub-
jects. For phosphate binder use, 96% (196/205) and 95%
(195/205) of cinacalcet and control subjects, respectively,
received binders at baseline and 91% (135/148) and 98%
(157/161), respectively, did so at week 26. The amount of
elemental calcium ingested was similar between cinacal-
cet and control subjects both at baseline and at week
26. The mean ± SD for the elemental calcium dose (mg
per main meal) was 677 (455) for cinacalcet subjects (N
= 87/200) and 622 (334) (N = 96/204) for control sub-
jects (P = NS) at baseline, and 741 (444) (N = 45/200)
and 644 (350) (N = 54/204), respectively, (P = NS)
at week 26.
DISCUSSION
This randomized, double-blind, placebo-controlled,
multicenter trial in 410 subjects with secondary HPT
on hemodialysis demonstrated that cinacalcet was ef-
fective in lowering PTH when either a first- or second-
generation 2-site PTH immunometric assay was used to
monitor response to treatment. Regression analyses re-
vealed statistically significant correlations between assays
at baseline and during weeks 13 to 26. The linear rela-
tionship between the 2 assays did not change after treat-
ment with cinacalcet. Percentage reductions in biPTH
and iPTH were 38% for each after treatment with cinacal-
cet. Approximately 60% of subjects treated with cinacal-
cet achieved a 30% or greater reduction from baseline
in either iPTH or biPTH, whereas only 10% to 11% of
subjects in the control group achieved this target. No
significant differences between treatment groups in the
percentage of subjects receiving vitamin D sterols or
phosphate binders, or in the amount of elemental calcium
ingested, were observed.
Several observational studies have reported statisti-
cally significant correlations between first- and second-
generation immunometric PTH assays for healthy indi-
viduals and patients with primary HPT [22–24]. Similar
correlations were reported in patients with ESRD, de-
spite a wide range of PTH concentrations and different
bone histomorphometric findings ranging from HPT to
adynamic bone disease [25–28]. In this study, we report a
strong correlation between PTH assays during prospec-
tive, double-blind treatment of dialysis patients with sec-
ondary HPT, indicating that results obtained using the
biPTH assay can be used to monitor response to therapy
with cinacalcet.
Because the correlation between plasma biPTH and
iPTH in both treatment groups was excellent in the
present study, a reasonable estimate of PTH(1–84) level
could be derived by multiplying iPTH results by 0.54
(baseline ratio equaled 0.52 and the week 13 to 26 ra-
tio equaled 0.56 for both treatment groups). This finding
is consistent with previous trials suggesting that approx-
imately 40% to 60% of total PTH detected by second-
generation tests in patients with renal failure is actually
PTH(1–84) [10], including a ratio of 64% in a retrospec-
tive study of hemodialysis patients that used the same
commercial tests as this study [28]. Based on the find-
ings of this study, the iPTH target of 150 to 300 pg/mL
recommended by the NKF-K/DOQITM guidelines [29]
corresponds to an approximate biPTH target range of 80
to 160 pg/mL. Although bone histomorphometry was not
assessed in this study, the consistent ratio between both
assays observed by us and others [10, 15, 16, 28], and the
similar correlations between biPTH or iPTH values and
BALP, suggest that biPTH and iPTH have similar utility
as predictors of bone health.
An advantage of this study was that the large num-
ber of subjects allowed for a meaningful analysis of the
demographic and laboratory parameters that might have
influenced the relationship between iPTH and (iPTH–
biPTH). Overall, the ratio of biPTH to (iPTH–biPTH)
was not significantly different between the cinacalcet and
control treatment groups during weeks 13 to 26 (1.15 vs.
1.20, respectively). Slight modifications to the biPTH to
(iPTH–biPTH) relationship may be observed based on
demographic characteristics and/or laboratory parame-
ters, and the trends observed in this study are discussed
below.
Several previous studies in animals and humans sug-
gested that intraglandular and peripheral metabolism of
PTH to different fragments is regulated by blood ionized
calcium concentrations [27, 30–34]. However, in these
earlier studies, metabolism into fragments that resem-
ble PTH(7–84) could not be assessed. When calcium
levels are low, relatively more full-length PTH(1–84) is
released from the parathyroid gland; whereas when cal-
cium levels are high, relatively more PTH fragments are
detected. Perhaps this regulation is designed to maxi-
mize the reabsorption of calcium in the distal tubule and
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the mobilization of calcium from bone during hypocal-
cemia, and to prevent further elevations of serum cal-
cium levels during hypercalcemia. In the current study,
higher serum calcium levels were associated with a de-
creased ratio between biPTH and (iPTH–biPTH) in
both the control and the cinacalcet groups; these re-
sults support earlier reports [30]. In addition, the ratio
was lower in the cinacalcet group than the control group
at both serum calcium levels examined, either because
cinacalcet enhances the effect of calcium at the calcium-
sensing receptor or because the distribution of calcium
values within each serum calcium subgroup of cinacalcet-
treated subjects is lower than in the subgroup of control
subjects.
Elevated serum phosphorus levels stimulate PTH se-
cretion [35]. A study by Chudek et al demonstrated that
reductions in serum phosphorus levels with sevelamer
treatment led to a decreased ratio of biPTH to iPTH
[36], suggesting that more full-length PTH was produced
when serum phosphorus levels were elevated. A signifi-
cant increase in the biPTH to (iPTH–biPTH) ratio was
observed for the highest serum phosphorus levels com-
pared with the lowest serum phosphorus levels in the
cinacalcet group; in the control group there was a trend
toward a decrease in the ratio of biPTH to (iPTH–biPTH)
with decreasing serum phosphorus levels. These results
are consistent with the observation of Chudek et al, and
are expected to maximize the renal excretion of phospho-
rus during hyperphosphatemia.
In general, demographic factors and other laboratory
parameters did not have consistent effects on the ratio of
biPTH to (iPTH–biPTH). In the cinacalcet group, sub-
jects under 65 years old had a higher ratio of biPTH to
(iPTH–biPTH) than subjects 65 years or older, but this
effect was not observed in the control group. A trend
for a higher biPTH to (iPTH–biPTH) ratio was observed
for non-white subjects, compared with white subjects, but
this only reached significance in the control group. The
increased severity of secondary HPT observed in blacks,
compared with whites, may contribute to this finding.
A significantly higher ratio was observed in cinacalcet-
treated subjects who had higher BALP levels, which is
not unexpected because PTH and BALP are highly cor-
related, but this effect was not observed in the control
group.
Initial analyses indicated that concurrent treatment
with vitamin D sterols increased the ratio of biPTH to
(iPTH–biPTH). Because many of the patients who en-
rolled in this study were not receiving vitamin D sterols
due to hypercalcemia, these analyses were redone, adjust-
ing for the serum calcium value. When the adjustment for
serum calcium was included, there was no difference in
the ratio by vitamin D use. Phosphate binder type used
also did not alter the biPTH/(iPTH–biPTH) ratio.
CONCLUSION
Multiple studies have demonstrated the ability of
cinacalcet therapy to reduce PTH levels as measured
by the first-generation immunometric PTH assay [19–21,
37]. In this prospective, randomized, double-blind study
of 410 subjects with secondary HPT receiving dialysis, we
demonstrate that treatment response to cinacalcet ther-
apy was nearly identical for iPTH and biPTH assays. The
ratio of biPTH to iPTH (approximately 54%) was consis-
tent throughout 6 months of cinacalcet or control treat-
ment, across a wide range of iPTH values. The biPTH to
(iPTH–biPTH) ratio was also consistent (approximately
1.2). Statistically significant variations in the ratio of
biPTH to (iPTH–biPTH) were observed with variations
in serum calcium. In conclusion, for hemodialysis patients
with secondary HPT, the newer second-generation PTH
assays appear to have comparable accuracy for monitor-
ing PTH response to cinacalcet therapy compared with
first-generation assays.
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